Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Country/Region as subject
Affiliation country
Publication year range
1.
Int J Mol Sci ; 23(15)2022 Jul 28.
Article in English | MEDLINE | ID: mdl-35955491

ABSTRACT

Crohn's disease (CD) is a complex, disabling, idiopathic, progressive, and destructive disorder with an unknown etiology. The pathogenesis of CD is multifactorial and involves the interplay between host genetics, and environmental factors, resulting in an aberrant immune response leading to intestinal inflammation. Due to the high morbidity and long-term management of CD, the development of non-pharmacological approaches to mitigate the severity of CD has recently attracted great attention. The gut microbiota has been recognized as an important player in the development of CD, and general alterations in the gut microbiome have been established in these patients. Thus, the gut microbiome has emerged as a pre-eminent target for potential new treatments in CD. Epidemiological and interventional studies have demonstrated that diet could impact the gut microbiome in terms of composition and functionality. However, how specific dietary strategies could modulate the gut microbiota composition and how this would impact host-microbe interactions in CD are still unclear. In this review, we discuss the most recent knowledge on host-microbe interactions and their involvement in CD pathogenesis and severity, and we highlight the most up-to-date information on gut microbiota modulation through nutritional strategies, focusing on the role of the microbiota in gut inflammation and immunity.


Subject(s)
Crohn Disease , Gastrointestinal Microbiome , Microbiota , Crohn Disease/therapy , Diet , Gastrointestinal Microbiome/physiology , Host Microbial Interactions , Humans , Inflammation/therapy
2.
Am J Physiol Endocrinol Metab ; 313(1): E1-E11, 2017 07 01.
Article in English | MEDLINE | ID: mdl-28325732

ABSTRACT

We tested the hypothesis that dietary whey protein isolate (WPI) affects the intestinal mechanisms related to energy absorption and that the resulting energy deficit is compensated by changes in energy balance to support growth. C57BL/6 mice were provided a diet enriched with WPI with varied sucrose content, and the impact on energy balance-related parameters was investigated. As part of a high-sucrose diet, WPI reduced the hypothalamic expression of pro-opiomelanocortin gene expression and increased energy intake. The energy expenditure was unaffected, but epididymal weight was reduced, indicating an energy loss. Notably, there was a reduction in the ileum gene expression for amino acid transporter SLC6a19, glucose transporter 2, and fatty acid transporter 4. The composition of the gut microbiota also changed, where Firmicutes were reduced. The above changes indicated reduced energy absorption through the intestine. We propose that this mobilized energy in the adipose tissue and caused hypothalamic changes that increased energy intake, acting to counteract the energy deficit arising in the intestine. Lowering the sucrose content in the WPI diet increased energy expenditure. This further reduced epididymal weight and plasma leptin, whereupon hypothalamic ghrelin gene expression and the intestinal weight were both increased. These data suggest that when the intestine-adipose-hypothalamic pathway is subjected to an additional energy loss (now in the adipose tissue), compensatory changes attempt to assimilate more energy. Notably, WPI and sucrose content interact to enable the component mechanisms of this pathway.


Subject(s)
Adiposity/physiology , Dietary Proteins/pharmacology , Energy Metabolism/drug effects , Gene Expression Regulation/drug effects , Intestinal Absorption/drug effects , Neuropeptides/genetics , Whey Proteins/pharmacology , Administration, Oral , Animals , Dietary Proteins/metabolism , Energy Intake/drug effects , Energy Metabolism/physiology , Hypothalamus/drug effects , Hypothalamus/metabolism , Intestinal Absorption/physiology , Male , Mice , Mice, Inbred C57BL , Neuropeptides/metabolism
3.
In. Administración de los Servicios de Salud del Estado (Uruguay : 2007-). Hacia una nueva dinámica institucional: [2010-2014]. [Montevideo?], ASSE, [2014?]. p.101-118, ilus.
Monography in Spanish | LILACS, UY-BNMED, BNUY | ID: biblio-1354071
4.
PLoS One ; 7(1): e30005, 2012.
Article in English | MEDLINE | ID: mdl-22279558

ABSTRACT

Preclinical disease models play an important role in the establishment of new treatment paradigms, identification of biomarkers and assessment of drug efficacy and safety. However, the accuracy of these models in context of the human disease are sometimes questioned, e.g. due to trials failing to confirm efficacy in humans. We suggest that one reason behind this gap in predictability may relate to how the preclinical data is analyzed and interpreted. In the present paper, we introduce a holistic approach to analyze and illustrate data in context of one of the most commonly used colitis models, i.e. the mouse dextran sulphate sodium (DSS) colitis model. Diseased mice were followed over time along disease progression and by use of tool pharmacological compounds activating nuclear hormone receptors, respectively. A new multivariate statistics approach was applied including principal component analysis (PCA) with treatment prediction subsequent to establishing the principal component analysis model. Thus, several studies could be overlaid and compared to each other in a new, comprehensive and holistic way. This method, named mouse colitis global property screening, appears applicable not only to any animal modelling series of studies but also to human clinical studies. The prerequisites for the study set up and calculations are delineated and examples of new learnings from the global property screening will be presented.


Subject(s)
Biomarkers/blood , Colitis/blood , Disease Models, Animal , Inflammatory Bowel Diseases/blood , Animals , Colitis/chemically induced , Colitis/drug therapy , Colon/drug effects , Colon/metabolism , Colon/pathology , Cytokines/blood , Dextran Sulfate , Female , Haptoglobins/metabolism , Holistic Health , Humans , Inflammation Mediators/blood , Inflammatory Bowel Diseases/diagnosis , Inflammatory Bowel Diseases/drug therapy , Liver X Receptors , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Orphan Nuclear Receptors/agonists , PPAR alpha/agonists , PPAR gamma/agonists , Principal Component Analysis
SELECTION OF CITATIONS
SEARCH DETAIL